Cas:5691-09-8 trans-2-Aminomethyl-1-cyclohexanol manufacturer & supplier

Chemical Name:trans-2-Aminomethyl-1-cyclohexanol

CAS.NO:5691-09-8

Synonyms:MFCD00145420;trans-2-aminomethyl-1-cyclohexanol

Molecular Formula:C₇H₁₅NO

Molecular Weight:129.20000

HS Code:2922199090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:226.4ºC at 760mmHg

Density:N/A

Index of Refraction:1.4905-1.4925

PSA:46.25000

Exact Mass:129.11500

LogP:1.19650

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like MFCD00145420 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,trans-2-aminomethyl-1-cyclohexanol physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,trans-2-aminomethyl-1-cyclohexanol Use and application,MFCD00145420 technical grade,usp/ep/jp grade.

Related News: The client needed full development and product readiness with an extremely short supply of the API. In addition, the scale-up batch was small because of the low volume of product demands of their orphan drug. L-Phenylglycine Methyl Ester Hydrochloride manufacturers For skin rash, the difference in response rates for anifrolumab versus placebo at week 52 were 13.5% SLE Disease Activity Index (SLEDAI), 15.5% British Isles Lupus Assessment Group index (BILAG) and 15.6% modified Cutaneous Lupus Erythematosus Disease Area and Severity Index (mCLASI). For arthritis, differences in response rates were 8.2% SLEDAI, 11.8% BILAG and 12.6% joint response. 2,1,3-Benzothiadiazole-4-sulfonamide suppliers In Massachusetts, where the bulk of Takeda’s U.S. operations are based since the Shire buyout, the Japanese pharma has been swiftly ramping up its cell therapy ambitions. In September, the company cut the ribbon on a new 24,000-square-foot R&D manufacturing center in Boston, which it said at the time would handle clinical development for three ongoing pipeline programs and two other prospects pegged to enter clinical development by the end of 2021. (4-fluoro-3-nitrophenyl)methanamine vendor & factory.